132 related articles for article (PubMed ID: 1565872)
1. Proliferative activity in epiretinal membranes. The use of the monoclonal antibody Ki-67 in proliferative vitreoretinal diseases.
Heidenkummer HP; Kampik A; Petrovski B
Retina; 1992; 12(1):52-8. PubMed ID: 1565872
[TBL] [Abstract][Full Text] [Related]
2. Proliferative activity and immunohistochemical cell differentiation in human epiretinal membranes.
Heidenkummer HP; Kampik A
Ger J Ophthalmol; 1992; 1(3-4):170-5. PubMed ID: 1483131
[TBL] [Abstract][Full Text] [Related]
3. [Comparative immunohistochemical studies of epiretinal membranes in proliferative vitreoretinal diseases].
Heidenkummer HP; Kampik A
Fortschr Ophthalmol; 1991; 88(3):219-24. PubMed ID: 1889766
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis and cell proliferation in proliferative retinal disorders: PCNA, Ki-67, caspase-3, and PARP expression.
Zhang X; Barile G; Chang S; Hays A; Pachydaki S; Schiff W; Sparrow J
Curr Eye Res; 2005 May; 30(5):395-403. PubMed ID: 16020270
[TBL] [Abstract][Full Text] [Related]
5. Indicators of oxidative tissue damage and inflammatory activity in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker.
Augustin AJ; Spitznas M; Koch F; Grus F; Böker T
Ger J Ophthalmol; 1995 Jan; 4(1):47-51. PubMed ID: 7728110
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis in proliferative vitreoretinal disorders: possible involvement of TGF-beta-induced RPE cell apoptosis.
Esser P; Heimann K; Bartz-schmidt KU; Fontana A; Schraermeyer U; Thumann G; Weller M
Exp Eye Res; 1997 Sep; 65(3):365-78. PubMed ID: 9299173
[TBL] [Abstract][Full Text] [Related]
7. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases.
Robbins SG; Mixon RN; Wilson DJ; Hart CE; Robertson JE; Westra I; Planck SR; Rosenbaum JT
Invest Ophthalmol Vis Sci; 1994 Sep; 35(10):3649-63. PubMed ID: 8088954
[TBL] [Abstract][Full Text] [Related]
8. Tenascin and decorin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy.
Hagedorn M; Esser P; Wiedemann P; Heimann K
Ger J Ophthalmol; 1993 Feb; 2(1):28-31. PubMed ID: 7679595
[TBL] [Abstract][Full Text] [Related]
9. Immunolocalization of integrins in proliferative retinal membranes.
Robbins SG; Brem RB; Wilson DJ; O'Rourke LM; Robertson JE; Westra I; Planck SR; Rosenbaum JT
Invest Ophthalmol Vis Sci; 1994 Aug; 35(9):3475-85. PubMed ID: 8056523
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical study of angiogenesis and proliferative activity in epiretinal membranes.
Tsanou E; Ioachim E; Stefaniotou M; Gorezis S; Charalabopoulos K; Bagli H; Peschos D; Psilas K; Agnantis NJ
Int J Clin Pract; 2005 Oct; 59(10):1157-61. PubMed ID: 16178982
[TBL] [Abstract][Full Text] [Related]
11. Cellular components of proliferative vitreoretinal membranes.
Kwak SI; Chung H; Lee J
Korean J Ophthalmol; 1991 Dec; 5(2):68-75. PubMed ID: 1812289
[TBL] [Abstract][Full Text] [Related]
12. Active scatter factor (HGF/SF) in proliferative vitreoretinal disease.
Briggs MC; Grierson I; Hiscott P; Hunt JA
Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3085-94. PubMed ID: 10967068
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of RAGE and its ligands in proliferative retinal disease.
Pachydaki SI; Tari SR; Lee SE; Ma W; Tseng JJ; Sosunov AA; Cataldergirmen G; Scarmeas N; Caspersen C; Chang S; Schiff WM; Schmidt AM; Barile GR
Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
[TBL] [Abstract][Full Text] [Related]
14. Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes.
Vinores SA; Campochiaro PA; Conway BP
Invest Ophthalmol Vis Sci; 1990 Jan; 31(1):14-28. PubMed ID: 1688833
[TBL] [Abstract][Full Text] [Related]
15. [Recurrent vitreoretinal membranes in intravitreal silicon oil tamponade. Morphologic and immunohistochemical studies].
Heidenkummer HP; Messmer EM; Kampik A
Ophthalmologe; 1996 Apr; 93(2):121-5. PubMed ID: 8652975
[TBL] [Abstract][Full Text] [Related]
16. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.
Abu El-Asrar AM; Struyf S; Kangave D; Geboes K; Van Damme J
Eur Cytokine Netw; 2006 Sep; 17(3):155-65. PubMed ID: 17194635
[TBL] [Abstract][Full Text] [Related]
17. Platelet-derived growth factor and basic fibroblast growth factor immunolocalized in proliferative retinal diseases.
Liang X; Li C; Li Y; Huang J; Tang S; Gao R; Li S
Chin Med J (Engl); 2000 Feb; 113(2):144-7. PubMed ID: 11775539
[TBL] [Abstract][Full Text] [Related]
18. Pathological changes in the vitreoretinal junction 1: epiretinal membrane formation.
Snead DR; James S; Snead MP
Eye (Lond); 2008 Oct; 22(10):1310-7. PubMed ID: 18344963
[TBL] [Abstract][Full Text] [Related]
19. Diverse NF-kappaB expression in epiretinal membranes after human diabetic retinopathy and proliferative vitreoretinopathy.
Harada C; Harada T; Mitamura Y; Quah HM; Ohtsuka K; Kotake S; Ohno S; Wada K; Takeuchi S; Tanaka K
Mol Vis; 2004 Jan; 10():31-6. PubMed ID: 14737065
[TBL] [Abstract][Full Text] [Related]
20. [Pathomorphology of membranes appearing in proliferative vitreoretinopathies].
Laudańska-Olszewska I; Omulecki W; Dziegielewski K; Pikulski Z; Omulecka A
Klin Oczna; 2006; 108(1-3):28-31. PubMed ID: 16883935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
